Scandinavian ChemoTech's Animal Care division receives orders from Australia and the US
Scandinavian ChemoTech's wholly owned subsidiary Vetiqure AB has received an order for vetIQure-TSE system from its distributor in Australia. This after a study with vetIQure received ethics approval. Vetiqure has also signed evaluation agreements with two clinics in the US. The total order value for both deals amounts to at least 17,000 euros.
Scandinavian ChemoTech announces that a university hospital in Australia within veterinary healthcare has today received ethics approval to conduct studies with vetIQure TSE, which has resulted in an order. This initial order from Gamma Gurus, ChemoTech's distributor in the country, was subject to positive ethics approval. Installation and training at the university hospital will take place during the month of May 2023.
Furthermore, the Company announces that Vetiqure in the USA yesterday signed its second evaluation agreement during the year, which also brings in revenue from sold treatment kits.
The total order value for these two deals amounts to at least EUR 17,000.
"It is very gratifying that our hard work is now beginning to bear fruit. The evaluation agreements in the US are of great strategic importance and indicate that our TSE technology is beginning to gain wider recognition in the US market. The ethics approval in Australia will mean that we can more actively process potential customers in the country. Early on in our collaboration, Gamma Gurus has demonstrated the large contact network it possesses and we have high hopes for continued success that will also spread to Human Care in Australia and New Zealand", says Scandinavian ChemoTech's CEO, Mohan Frick in a comment.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
